Bringing Biology and Testing Expertise Together Online

Drug discovery rarely moves in a straight line through isolated disciplines. As therapeutic modalities diversify, spanning small molecules, oligonucleotides, cell and gene therapies, and beyond, the questions researchers must ask increasingly impact multiple development stages. A team that identifies a promising hit needs to know how they will later be expected to prove that molecule’s behavior in vivo. A team validating a target needs a clear path toward investigational new drug (IND)-enabling studies. Drug developers are looking for partners who can support this full journey, not just a single step along the way.

To better support our partner as this shift progresses, WuXi AppTec is also shifting its online presence. In late October 2026, WuXi Biology and Testing Divisions will launch a new combined website under one URL, bringing together information and resources across capabilities including:

• Discovery Biology, from target identification and hit finding to in vitro assay development and in vivo pharmacology
• DMPK, from in vitro ADME to in vivo pharmacokinetics and metabolism studies
• Bioanalysis, supporting small molecules, biologics, and emerging therapeutic modalities
• Safety Assessment Services, from early safety evaluation through IND-enabling programs and beyond

What is Changing

WuXi AppTec’s new unified site is designed to provide visitors with a single, integrated resource for exploring capabilities and expertise from early drug discovery through preclinical IND-enabling work. This change reflects the way customers already think about drug discovery and development: as a continuous journey from target identification through IND submission, rather than a series of disconnected services.

A visitor researching early discovery best practices and capabilities such as target identification, screening, and hit identification and optimization will now be able to see, in one place, how that work connects directly to downstream distribution, metabolism, and pharmacokinetics (DMPK), bioanalysis, and GLP toxicology. When drug developers enter the process with a broader view of capabilities and testing needs, they can build smarter, more efficient strategies to advance candidates through the development journey.

What is Not Changing

While the website is changing, the divisions it represents are not. Biology andTesting will continue to operate under their existing structure, each maintaining distinct expertise and strategic offerings.

For customers, this means business as usual. Points of contact, account management, and existing relationships remain the same. Contracting, proposal, and quote processes are unaffected, and customers will continue to engage with each division as they do today. Data handoffs, sample logistics, and project workflows between Biology and Testing will remain unchanged.

What to Look Forward To

The consolidated website is intended to make it easier to discover how WuXi AppTec’s capabilities work together. Visitors will find a single, streamlined destination to explore the full spectrum of drug discovery and preclinical services, with clearer pathways between adjacent capabilities.

Developers focused on early discovery may not always consider downstream bioanalysis or toxicology needs, even when these considerations can influence how a program advances. A unified site surfaces insights on current and adjacent testing phases more naturally, so website visitors researching one stage of development can more easily find related expertise on the next. It is also better suited to serving multiple audiences, from scientists evaluating technical fit to business stakeholders assessing the scope of a partnership.

For drug developers, this means less time piecing together information across separate websites and greater visibility into how early discovery connects with downstream development. Bringing related scientific resources and capabilities into one digital experience, the new website will make it easier to identify relevant expertise, anticipate adjacent development needs, and navigate the discovery-to-IND journey. It is a more comprehensive and connected view of our end-to-end capabilities that will help developers deliver groundbreaking treatments to patients around the world.

A Final Word

Drug development increasingly requires scientists and development teams to consider how decisions at one stage can influence what comes next. The new combined Biology and Testing website is designed to make those connections easier to see and navigate—from early discovery through IND-enabling development.

We look forward to welcoming visitors to the new website in late October 2026 and providing a simpler way to explore WuXi AppTec’s expertise across the discovery-to-IND journey.

FAQs

Q: Are WuXi Biology and Testing merging?
A: No. The Biology and Testing divisions are not merging; only their websites are being combined. Biology and Testing will continue to support ongoing work through their existing teams and processes.

Q: Will my current point of contact change?
A: No, existing customer relationships and points of contact remain unchanged. Customers can continue working with their current teams as they do today.

Q: Will my current project or study be affected?
A: No, the website change does not affect current project workflows or existing customer engagements. WuXi Biology and Testing will continue to support ongoing work through their existing teams and processes.

Q: Will contracting or quoting processes change?
A: No, contracting, proposal, and quoting processes will remain unchanged. Customers can continue to work with their existing contacts and teams as they do today.

Q: What will happen to bookmarked content or existing page links?
A: Existing links will remain accessible for a designated transition period. This will give visitors time to become familiar with the new website and update bookmarks as needed.

Q: Will I still be able to find specific Biology or Testing capabilities easily?
A: Yes, the combined website is designed to make it easier to find specific Biology and Testing capabilities while also providing clearer pathways between related services across discovery and preclinical development.